An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Lubricant Eye Drops; Timolol; Travoprost

Criteria

Inclusion Criteria:

• Ocular hypertension or glaucoma that requires treatment with medication

• Have a best corrected visual acuity (BCVA) of 20/100 or better in both eyes

Exclusion Criteria:

• History of LASIK, LASEK, RK, and/or PRK in the study eye(s)

• History of any intraocular surgery or glaucoma laser surgery in the study eye(s) within 3 months

• Use of topical, periorbital, intravitreal or systemic steroid within 3 months or expected use during the course of study